Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients

Antonella Torosantucci, Mario Tumbarello, Carla Bromuro, Paola Chiani, Brunella Posteraro, Maurizio Sanguinetti, Roberto Cauda, Antonio Cassone

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-Candida immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.

Original languageEnglish
Article number2722
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Glucans
Candida albicans
Immunity
Antibodies
Candida
Proteins
Candidemia
APACHE
Septic Shock
Cell Wall
Survivors
Morbidity
Mortality
Infection
Serum

ASJC Scopus subject areas

  • General

Cite this

Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. / Torosantucci, Antonella; Tumbarello, Mario; Bromuro, Carla; Chiani, Paola; Posteraro, Brunella; Sanguinetti, Maurizio; Cauda, Roberto; Cassone, Antonio.

In: Scientific Reports, Vol. 7, No. 1, 2722, 01.12.2017.

Research output: Contribution to journalArticle

Torosantucci, Antonella ; Tumbarello, Mario ; Bromuro, Carla ; Chiani, Paola ; Posteraro, Brunella ; Sanguinetti, Maurizio ; Cauda, Roberto ; Cassone, Antonio. / Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{2ade7a0db4d74418b049f846e12192cc,
title = "Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients",
abstract = "Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-Candida immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.",
author = "Antonella Torosantucci and Mario Tumbarello and Carla Bromuro and Paola Chiani and Brunella Posteraro and Maurizio Sanguinetti and Roberto Cauda and Antonio Cassone",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02977-6",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients

AU - Torosantucci, Antonella

AU - Tumbarello, Mario

AU - Bromuro, Carla

AU - Chiani, Paola

AU - Posteraro, Brunella

AU - Sanguinetti, Maurizio

AU - Cauda, Roberto

AU - Cassone, Antonio

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-Candida immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.

AB - Sera from candidemic and non-candidemic subjects were examined for antibodies against the cell wall β1,3- and β1,6-glucans, as well as the β-glucan-associated protein MP65 of Candida species. Although antibodies against each of the above components were detected in all subjects, candidemic patients had lower antibody titers against β1,3-glucan, but higher antibody titers against β1,6-glucan and MP65, than non-candidemic subjects. The elevated levels of anti-β1,6-glucan and -MP65 antibodies found in candidemic patients were independent on the patient risk category, APACHE II score, presence of co-morbidities, β1,3-glucanemia level, Candida isolate, and antifungal treatment. Interestingly, however, the anti-MP65, but not the anti-β1,6-glucan antibodies, of candidemic patients had higher titers in survivors than in non-survivors, particularly in those subject categories with the highest mortality (>65-years old, diabetic, or septic shock patients). Thus, candidemic patients are capable of boosting anti-Candida immune responses upon infection, and some of these responses might be associated to the generation of protective immunity in patients with candidemia.

UR - http://www.scopus.com/inward/record.url?scp=85020016417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020016417&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02977-6

DO - 10.1038/s41598-017-02977-6

M3 - Article

AN - SCOPUS:85020016417

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2722

ER -